Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Anza Memon
Study ID
NCT07181811
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments — OTHER
    The cognitive and fatigue assessments administered in this study are not currently part of the standard clinical care for multiple sclerosis patients on Ocrelizumab. By prospectively assigning participants to undergo these additional assessments, this aspect of the study is considered investigational, and findings may contribute to clinical decision-making regarding the incorporation of cognitive and fatigue assessments into routine management of multiple sclerosis conditions.

Study Details

This study seeks to assess the effects of long-term ocrelizumab therapy on fatigue (extreme tiredness) as well as cognition (thinking and reasoning skills, such as memory, learning and attention), in veterans with multiple sclerosis. The evaluation will involve cognitive assessment scales (to assess memory, attention and learning abilities), clinical evaluations (to assess nerve function and ability to move), and patient-reported outcome measures (in which you will answer questions about your tiredness, sleep and how you function in daily life). These assessments will occur at baseline (visit 1), 6 month (Visit-2) and 12 months (visit 3) to track changes over time.

Key Dates

Start date
Sep 30, 2025
Status verified
Sep 2025
Primary completion
Jun 1, 2028
Completion
Jun 1, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Ocrelizumab Arm
    This is a prospective, interventional study involving 30 subjects who have been diagnosed with multiple sclerosis and being treated with Ocrelizumab for at least one year.

Primary Outcome Measure

Change in global cognitive performance [ Time Frame: Baseline to 12 months. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
John D. Dingell VA Medical CenterDetroitMichigan48201
Lynn Huber, MBA
[email protected]
3135763106
Sara Omar, MSc
[email protected]
313-576-1485
Anza Memon, M.D, FAAN (PRINCIPAL_INVESTIGATOR)
Kyrstina Mariouw, PhD (SUB_INVESTIGATOR)

Find similar trials in Detroit, MI

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
John D. Dingell VA Medical Center· Detroit, MI

Related Studies